Equities research analysts predict that Maximus, Inc. (NYSE:MMS) will post $630.23 million in sales for the current quarter, according to Zacks. Five analysts have provided estimates for Maximus’ earnings, with the lowest sales estimate coming in at $623.28 million and the highest estimate coming in at $635.60 million. Maximus reported sales of $607.56 million in the same quarter last year, which indicates a positive year over year growth rate of 3.7%. The company is scheduled to issue its next quarterly earnings results on Thursday, February 8th.

On average, analysts expect that Maximus will report full-year sales of $630.23 million for the current year, with estimates ranging from $2.51 billion to $2.53 billion. For the next financial year, analysts forecast that the business will report sales of $2.66 billion per share, with estimates ranging from $2.62 billion to $2.74 billion. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for Maximus.

A number of research analysts have weighed in on MMS shares. Zacks Investment Research downgraded Maximus from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Robert W. Baird reiterated a “hold” rating and issued a $64.00 price objective on shares of Maximus in a research report on Friday, September 1st. Canaccord Genuity cut their price objective on shares of Maximus from $62.00 to $61.00 and set a “hold” rating for the company in a research report on Friday, November 10th. Finally, Maxim Group set a $66.00 target price on shares of Maximus and gave the company a “hold” rating in a report on Thursday, August 3rd. Two analysts have rated the stock with a sell rating and six have given a hold rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $64.33.

Shares of Maximus (NYSE MMS) opened at $69.08 on Friday. The company has a market cap of $4,490.00, a PE ratio of 21.78, a PEG ratio of 2.54 and a beta of 1.32. Maximus has a twelve month low of $51.74 and a twelve month high of $69.20.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, November 30th. Shareholders of record on Wednesday, November 15th were issued a $0.045 dividend. This represents a $0.18 dividend on an annualized basis and a yield of 0.26%. The ex-dividend date of this dividend was Tuesday, November 14th. Maximus’s dividend payout ratio is 5.68%.

In other Maximus news, insider Mark Andrekovich sold 5,594 shares of the firm’s stock in a transaction that occurred on Wednesday, November 22nd. The stock was sold at an average price of $67.23, for a total value of $376,084.62. Following the completion of the sale, the insider now owns 27,996 shares of the company’s stock, valued at $1,882,171.08. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Bruce Caswell sold 8,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $60.23, for a total value of $481,840.00. Following the completion of the transaction, the president now owns 35,904 shares in the company, valued at approximately $2,162,497.92. The disclosure for this sale can be found here. Over the last three months, insiders have sold 81,367 shares of company stock worth $5,190,663. 3.10% of the stock is currently owned by insiders.

A number of hedge funds have recently modified their holdings of MMS. Acrospire Investment Management LLC boosted its stake in Maximus by 17.6% during the 2nd quarter. Acrospire Investment Management LLC now owns 2,000 shares of the health services provider’s stock valued at $125,000 after purchasing an additional 300 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Maximus by 10.2% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,367 shares of the health services provider’s stock worth $148,000 after buying an additional 220 shares in the last quarter. First Bank & Trust increased its stake in Maximus by 4.2% in the 2nd quarter. First Bank & Trust now owns 2,507 shares of the health services provider’s stock worth $157,000 after buying an additional 101 shares in the last quarter. Intl Fcstone Inc. purchased a new stake in Maximus in the 2nd quarter worth $201,000. Finally, GW Henssler & Associates Ltd. purchased a new position in shares of Maximus during the second quarter valued at about $205,000. 95.22% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: “$630.23 Million in Sales Expected for Maximus, Inc. (MMS) This Quarter” was originally posted by American Banking News and is the property of of American Banking News. If you are viewing this news story on another domain, it was stolen and republished in violation of U.S. and international copyright laws. The original version of this news story can be accessed at https://www.americanbankingnews.com/2017/12/01/630-23-million-in-sales-expected-for-maximus-inc-mms-this-quarter-2.html.

About Maximus

MAXIMUS, Inc provides business process services (BPS) to government health and human services agencies. The Company operates through three segments: U.S. Federal Services, Health Services and Human Services. The U.S. Federal Services segment provides BPS and program management for large government programs, independent health review and appeals services for both the United States Federal Government, and state-based programs and technology solutions for civilian federal programs.

Get a free copy of the Zacks research report on Maximus (MMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Maximus (NYSE:MMS)

Receive News & Ratings for Maximus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maximus Inc. and related companies with MarketBeat.com's FREE daily email newsletter.